{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T22:24:25Z","timestamp":1776896665065,"version":"3.51.2"},"reference-count":19,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Brain and Behavior"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current German and European guidelines suggest migraine patients undertake a treatment break after 9 to 12 months of treatment with CGRP (pathway) monoclonal antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical routine data of highly resistant migraine patients were analyzed before treatment with CGRP monoclonal antibodies (baseline), after 12 months of treatment, and following a treatment break between November 2018 and December 2020 in the West German Headache Centre, University Hospital Essen, Germany. Monthly migraine days (MMD), monthly headache days (MHD), and days of acute medication intake (AMD) were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Complete clinical data from 46 migraine patients (14 episodic migraine (EM), 32 chronic migraine (CM) patients) treated with erenumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a040), galcanezumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a04), and fremanezumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a02) were analyzed. The mean number of MMDs among EM and CM patients after 12 months of CGRP antibody treatment increased during the treatment break by 5.18 (SE 0.92,\n                      <jats:italic>p\u00a0<\/jats:italic>\n                      &lt;\u00a0.001) and 5.06 (SE 1.22,\n                      <jats:italic>p\u00a0=\u00a0<\/jats:italic>\n                      .003) days, respectively. There was an increased intake of acute medications among episodic (4.72, SE 0.87,\n                      <jats:italic>p\u00a0<\/jats:italic>\n                      =\u00a0.004) and chronic migraine patients (3.01, SE 1.08,\n                      <jats:italic>p\u00a0<\/jats:italic>\n                      =\u00a0.013) during treatment break. Eighty\u2010three percent of patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a038) were dissatisfied with the mandatory treatment break. All patients continued with a CGRP (pathway) monoclonal antibody after the mandatory treatment break.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A mandatory break in CGRP (pathway) monoclonal antibody therapy had a negative short\u2010term impact on migraine patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/brb3.2662","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T15:14:13Z","timestamp":1654874053000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Real\u2010world evidence following a mandatory treatment break after a 1\u2010year prophylactic treatment with calcitonin gene\u2010related peptide (pathway) monoclonal antibodies"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7090-0077","authenticated-orcid":false,"given":"Michael","family":"Nsaka","sequence":"first","affiliation":[{"name":"Department of Neurology and Centre for Translational Neuro\u2010 and Behavioural Sciences (C\u2010TNBS), West German Headache Center University Hospital Essen, University Duisburg\u2010Essen  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armin","family":"Scheffler","sequence":"additional","affiliation":[{"name":"Department of Neurology and Centre for Translational Neuro\u2010 and Behavioural Sciences (C\u2010TNBS), West German Headache Center University Hospital Essen, University Duisburg\u2010Essen  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7461-6620","authenticated-orcid":false,"given":"Sebastian","family":"Wurthmann","sequence":"additional","affiliation":[{"name":"Department of Neurology and Centre for Translational Neuro\u2010 and Behavioural Sciences (C\u2010TNBS), West German Headache Center University Hospital Essen, University Duisburg\u2010Essen  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Schenk","sequence":"additional","affiliation":[{"name":"Department of Neurology and Centre for Translational Neuro\u2010 and Behavioural Sciences (C\u2010TNBS), West German Headache Center University Hospital Essen, University Duisburg\u2010Essen  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[{"name":"Department of Neurology and Centre for Translational Neuro\u2010 and Behavioural Sciences (C\u2010TNBS), West German Headache Center University Hospital Essen, University Duisburg\u2010Essen  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Glas","sequence":"additional","affiliation":[{"name":"Department of Neurology and Centre for Translational Neuro\u2010 and Behavioural Sciences (C\u2010TNBS), Division of Clinical Neurooncology University Hospital Essen, University Duisburg\u2010Essen  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagny","family":"Holle","sequence":"additional","affiliation":[{"name":"Department of Neurology and Centre for Translational Neuro\u2010 and Behavioural Sciences (C\u2010TNBS), West German Headache Center University Hospital Essen, University Duisburg\u2010Essen  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1066-0"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13657"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420983282"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-05022-z"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70272-7"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1083-7437"},{"key":"e_1_2_10_8_1","unstructured":"Diener H.\u2010C. Gaul C. Kropp P. & et\u00a0al.Therapy of migraine attacks and migraine prophylaxis S\u20101 Guidelines 2018 in: German Society of Neurologists Guidelines for Diagnostics and Therapy in Neurology.https:\/\/www.dgn.org\/leitlinien"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211014616"},{"issue":"1","key":"e_1_2_10_10_1","first-page":"17","article-title":"Migraine Headache Prophylaxis. Christus Santa Rosa Family Medicine Residency Program, San Antonio, Texas","volume":"99","author":"Hien H.","year":"2019","journal-title":"American Family Physician"},{"issue":"1","key":"e_1_2_10_11_1","first-page":"1","article-title":"The international classification of headache disorders (2nd ed)","volume":"24","author":"International Headache Society","year":"2004","journal-title":"Cephalalgia"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1996.1605337.x"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1018-8"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0955-y"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01151-0"},{"key":"e_1_2_10_16_1","first-page":"1212","article-title":"Erenumab discontinuation after 12\u2010month treatment. A multicentric, observational real\u2010life study","volume":"10","author":"Schiano di Cola F.","year":"2021","journal-title":"Neurology Clinical Practice"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.6.754"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13508"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01363-y"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1991.1106251.x"}],"container-title":["Brain and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.2662","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/brb3.2662","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.2662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T03:09:38Z","timestamp":1692932978000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/brb3.2662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1002\/brb3.2662"],"URL":"https:\/\/doi.org\/10.1002\/brb3.2662","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/BRB3.2662\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.2662\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.2662\/v1\/decision1","asserted-by":"object"}]},"ISSN":["2162-3279","2162-3279"],"issn-type":[{"value":"2162-3279","type":"print"},{"value":"2162-3279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]},"assertion":[{"value":"2022-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2662"}}